Top 10 Stocks

  • Stocks
  • IPO
  • Mutual FundsMF

© 2024 top10stocks.in. All Rights Reserved.

About UsContactTerms and ConditionsPrivacy PolicySitemap
    1. Home
    2. /
    3. IPOs
    4. /
    5. AKUMS

    Akums Drugs and Pharmaceuticals Limited

    CLOSED

    IPO Date: 30 Jul - 1 Aug 2024

    Listing Date: 6 Aug 2024

    Price Range

    646 to 679

    Issue Size

    1856.74 Cr

    Min Investment

    ₹14,212

    Lot Size

    22 Shares

    View IPO Document

    Schedule of Akums Drugs and Pharmaceuticals Limited

    Issue open date

    30 Jul 2024

    Issue close date

    1 Aug 2024

    UPI mandate deadline

    1 Aug 2024 (5 PM)

    Allotment finalization

    2 Aug 2024

    Share credit

    5 Aug 2024

    Listing date

    6 Aug 2024

    Mandate end date

    16 Aug 2024

    Issue size

    Funds Raised in the IPOAmount
    Overall1856.74 Cr
    Fresh Issue0 Cr
    Offer for Sale0 Cr

    Allotment DetailsNew

    Allotment TimelineDetails
    Allotment Date2 Aug 2024
    Allotment Link{Link}

    Grey Market PremiumNew

    Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.

    DateIpo PriceGMPEstimated Listing Price
    6 Aug 2024₹679₹43₹722 (6.33%)
    5 Aug 2024₹679₹43₹722 (6.33%)
    4 Aug 2024₹679₹86₹765 (12.67%)
    3 Aug 2024₹679₹99₹778 (14.58%)
    2 Aug 2024₹679₹124₹803 (18.26%)
    1 Aug 2024₹679₹141₹820 (20.77%)
    31 Jul 2024₹679₹170₹849 (25.04%)
    30 Jul 2024₹679₹177₹856 (26.07%)
    29 Jul 2024₹679₹211₹890 (31.08%)
    28 Jul 2024₹679₹180₹859 (26.51%)
    27 Jul 2024₹679₹170₹849 (25.04%)

    Performance Akums Drugs and Pharmaceuticals Limited

    Issue PriceListing GainCurrent Market PriceP/L
    646 to 679₹ 6084 (17.27%) ₹ 503.6-25.83%

    About Akums Drugs and Pharmaceuticals Limited

    Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs). As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few. The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023). The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF). As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.

    Founded in2004
    Managing director
    Parent organization

    Financial Overview

    Strengths

      Risks

        Subscription Figures

        CategorySubscription (No. of times)
        Qualified Institutional Buyers (QIBs)90.09
        Non-Institutional Investors (NIIs)42.1
        Retail Individual Investors (RIIs)20.8
        Employee4.14
        Total63.44